LigaSure™ Maryland

September 11, 2019 Luis Villanueva

LigaSure™ Maryland 

Mandíbula abierta y sellador / divisor laparoscópico con nano revestimiento

El nano revestimiento antiadherente mejora el rendimiento del dispositivo de mandíbula LigaSure ™ Maryland. Ahora puede agarrar, cortar, diseccionar y sellar de manera confiable el tejido y los vasos1, con menos interrupciones por acumulación de escara, 2, †† pegado, 3, ‡ y limpiezas de mandíbula.3, ‡ Para que los pacientes experimenten procedimientos más eficientes.2, ‡

  • † Eschar buildup assessed using optical imaging analysis after 60 seal and divide cycles.
  • ‡ Instances of tissue sticking to jaws measured over 110 seals per device.
  • § Cleaning effectiveness assessed after each of two cleaning cycles.
  • Ω When compared to the surgeon’s primary device, 23 out of 32 surveyed agreed.
  • †† 31 out of 33 surgeons surveyed agreed.
  • §§ 32 out of 32 surgeons surveyed agreed.
  • ΩΩ 33 out of 33 surgeons surveyed agreed. 
  • †† 21 out of 32 surgeons surveyed agreed.
  • ‡‡‡ 30 out of 33 surgeons surveyed agreed.
  • ‡‡‡ Based on data from 2001 through FY17.
  • 1. LigaSure™ Maryland Jaw Sealer/Divider, Nano-Coated [instructions for use]. Boulder, CO: Medtronic; 2016.
  • 2. Based on internal test report #RE00071599, LF19XX MJC marketing claims report conducted on porcine tissue. Feb. 7 to Feb. 22, 2017.
  • 3. Based on internal test report #RE00073194 , Tissue sticking comparison of the Ethicon G2™*, Voyant™* 5 mm Fusion, LigaSure™ LF1737, and LigaSure™ LF1937 devices conducted on porcine tissue using the Force Triad™ energy platform. Jan. 18, 2017.
  • 4. Based on internal test report #R0035742, Maryland validation labs: Independent surgeon feedback collected during porcine labs in Houston and Los Angeles. April 16 to 18 and April 30 to May 3, 2013.
  • 5. Based on internal test report #RE00071598, Maryland validation labs: Independent surgeon feedback collected during porcine labs in Houston and Los Angeles. April 16 to 18 and April 30 to May 3, 2013.
  • 6. Based on internal test report #RE00070396 Rev A, Verification of the LF1923/LF1937/LF1944 Maryland devices in a renal bench burst study: iterations Maryland. Nov. 7–10, 2016.
  • 7. Based on internal test report #R0064457, LigaSure™ device renal bench burst pressure evaluation of the Valleylab™ FT10 energy platform. May 3, 2015.
  • 8. Based on internal report #US161132(1), Sales data from FY01 to FY17. July 2017.
  • 9. Based on internal test report #RE00025819 Rev A, LigaSure™ device data sources for VLFT10 white papers. September 2015.
  • 10. Based on internal test report #RE00005503, Verification report: GLP acute animal lab: LigaSure™ device preclinical evaluation of Valleylab™ FT10 energy platform. May 19, 2015.
  • 11. Based on internal test report #RE00005401 Rev A, Product validation of Valleylab™ FT10 energy platform: surgeon and nurse evaluation in simulated use. Jan. 27 to 30, 2015 and Feb. 24 to 27, 2015.
Previous Article
LigaSure™ Exact

No More Articles